Published July 21, 2026
Pfizer and plaintiffs' leadership signed a Master Settlement Agreement on July 21, 2026, converting the tentative framework reported earlier this summer into a binding deal covering the federal Depo-Provera meningioma litigation.
More than 6,200 lawsuits are now pending in the federal multidistrict litigation, and Pfizer estimates the signed agreement could resolve roughly 80% of those cases. With the deal in place, the first bellwether trial, which had been scheduled for December 2026, has been taken off the court's calendar.
Registration for the settlement is expected to be completed by November 2026, with claims processing and the first payments projected to begin in the first quarter of 2027. The settlement's tiers, medical proof requirements, and individual payment amounts haven't been made public yet.
As with the earlier tentative framework, this settlement only reaches cases filed in the federal MDL. State court cases — including hundreds pending in Delaware, along with cases in New York and New Mexico — remain on entirely separate tracks and are unaffected.
If you used Depo-Provera and were later diagnosed with a meningioma, see Atumio's Depo-Provera case page for a free eligibility review, or start a case review directly.